117 related articles for article (PubMed ID: 25046419)
21. [Current outcomes and future directions in the chemotherapy of lung cancer].
Hara N
Fukuoka Igaku Zasshi; 1993 Sep; 84(9):389-94. PubMed ID: 8225159
[No Abstract] [Full Text] [Related]
22. [Outpatient drug therapy in non-small cell lung cancer].
Kobayashi K; Sakai H; Yoneda S
Nihon Rinsho; 2002 May; 60 Suppl 5():707-11. PubMed ID: 12101768
[No Abstract] [Full Text] [Related]
23. Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
Shigemitsu H; Kuschner WG
N Engl J Med; 2001 Mar; 344(9):689-90. PubMed ID: 11229341
[No Abstract] [Full Text] [Related]
24. Complexities of quality of life analysis in non-small cell lung cancer.
Temel J
J Support Oncol; 2007 Jan; 5(1):30-1. PubMed ID: 17265784
[No Abstract] [Full Text] [Related]
25. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.
Sangha R; Lara PN; Mack P; Gandara DR
Clin Lung Cancer; 2008; 9 Suppl 3():S90-1. PubMed ID: 19419929
[No Abstract] [Full Text] [Related]
26. [Molecular-targeted drug for non-small cell lung cancer].
Okamoto I
Nihon Rinsho; 2012 Nov; 70 Suppl 8():438-42. PubMed ID: 23513880
[No Abstract] [Full Text] [Related]
27. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology?
Einhorn LH
J Clin Oncol; 2008 Jul; 26(21):3485-6. PubMed ID: 18506022
[No Abstract] [Full Text] [Related]
28. Palliative benefits of chemotherapy treatment in non-small cell lung cancer may be underappreciated.
J Support Oncol; 2006 Feb; 4(2):61. PubMed ID: 16499116
[No Abstract] [Full Text] [Related]
29. [Erlotinib. A new option for non-small cell lung cancer].
Polk B
Med Monatsschr Pharm; 2006 Jan; 29(1):4-6. PubMed ID: 16463547
[No Abstract] [Full Text] [Related]
30. Palliative chemotherapy for non-small cell lung cancer: a measured dose of reality.
Kalemkerian GP
J Support Oncol; 2007 Jan; 5(1):27-8. PubMed ID: 17265783
[No Abstract] [Full Text] [Related]
31. [Established new drugs in the chemotherapy of non-small-cell lung carcinoma (NSCLC)].
Serke M
Dtsch Med Wochenschr; 2000 Feb; 125(8):225. PubMed ID: 10723459
[No Abstract] [Full Text] [Related]
32. Non-small cell lung cancer: from targeted therapy to tailored therapy.
Malgieri S; Feliciano S; Bosso D; Federico P; Palmieri G; De Placido S; Di Lorenzo G; Buonerba C
Expert Opin Pharmacother; 2012 Sep; 13(13):1817-9. PubMed ID: 22803703
[No Abstract] [Full Text] [Related]
33. Adjuvant chemotherapy in patients 80-89 years of age with non-small cell lung cancer.
Altundag O; Ates M; Atik MA; Altundag K
Eur J Cardiothorac Surg; 2005 Dec; 28(6):911-2; author reply 912. PubMed ID: 16242942
[No Abstract] [Full Text] [Related]
34. New drug to treat most common lung cancer.
FDA Consum; 2005; 39(1):3. PubMed ID: 15818792
[No Abstract] [Full Text] [Related]
35. [Personalized, targeted treatment of non-small cell lung cancer].
Wolf J
Dtsch Med Wochenschr; 2011 Mar; 136(10):480-5. PubMed ID: 21365525
[No Abstract] [Full Text] [Related]
36. Vinorelbine for treatment of advanced non-small-cell lung cancer.
Med Lett Drugs Ther; 1995 Aug; 37(955):72-3. PubMed ID: 7630328
[No Abstract] [Full Text] [Related]
37. The evolving role of histology in the treatment of non-small cell lung cancer.
Rana N; Khurshid H
Med Health R I; 2010 Oct; 93(10):317-9. PubMed ID: 21284271
[No Abstract] [Full Text] [Related]
38. [Treatment of lung cancer: critical review of new agents].
Spataro V
Rev Med Suisse; 2005 Feb; 1(8):575-81. PubMed ID: 15794308
[No Abstract] [Full Text] [Related]
39. [Non-small cell lung cancer: 1) Molecular-target therapy].
Muguruma H; Yano S; Sone S
Nihon Naika Gakkai Zasshi; 2003 Jul; 92(7):1284-90. PubMed ID: 12924275
[No Abstract] [Full Text] [Related]
40. [Biological therapy in non-small-cell lung cancer (NSCLC)].
Souquet PJ
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S53-4S56. PubMed ID: 15687996
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
